Plaintiffs Fear Retaliation In MiraLax Antitrust Suit

Law360, New York (April 22, 2011, 4:10 PM EDT) -- Plaintiffs in a putative antitrust class action accusing Braintree Laboratories Inc. of initiating baseless patent litigation to block a generic version of the laxative MiraLax asked a Delaware federal court Thursday to bar the company from retaliating against them.

Rochester Drug Cooperative Inc., Louisiana Wholesale Drug Co. and Meijer Inc. — which bought MiraLax directly from Braintree at what they claim was an inflated cost — sought an injunction preventing Braintree from its allegedly retaliatory termination of their supplier relationships, pending a final decision on their...
To view the full article, register now.